• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    Mirati Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Updates

    5/9/23 4:01:00 PM ET
    $MRTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $MRTX alert in real time by email

    SAN DIEGO, May 9, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, today announced financial results for the first quarter 2023 along with recent pipeline and corporate updates.

    "Today we are pleased to share the significant progress made during the first quarter of 2023, highlighted by our first full quarter of sales for KRAZATI®, which we believe is the best-in-class KRASG12C inhibitor. This is just the beginning of our journey with KRAZATI®, as we continue to advance our broad development plan in lung cancer and across other indications and lines of therapy," said David Meek, chief executive officer, Mirati Therapeutics, Inc. "In addition, we advanced our robust portfolio of potential best-in-class clinical programs, including MRTX1133, our KRASG12D inhibitor, MRTX1719, our MTA cooperative PRMT5 inhibitor, MRTX0902, our SOS1 inhibitor and sitravatinib, our TAM receptor inhibitor. Looking ahead, we remain committed to executing on our strategy to advance our pipeline of targeted oncology programs to positively impact the lives of people living with cancer."

    Pipeline Updates

    Adagrasib (Potent and selective KRASG12C inhibitor)

    • The Company presented updated clinical data for adagrasib as a targeted treatment for KRASG12C-mutated advanced pancreatic ductal adenocarcinoma (PDAC), biliary tract cancer and other solid tumors at the April session of the American Society of Clinical Oncology (ASCO) Plenary Series Program. In addition, the Journal of Clinical Oncology published these findings as a Rapid Communication. (View Release)
    • Adagrasib was included as the only KRAS inhibitor in the National Comprehensive Cancer Network guidelines for Central Nervous System Cancers for patients with KRASG12C -mutated non-small cell lung cancer (NSCLC) with central nervous system (CNS) metastases and for KRASG12C-mutation positive pancreatic adenocarcinoma cancer patients.
    • The Company is on track to complete supplemental New Drug Application (sNDA) for third-line and beyond colorectal cancer by year-end 2023.
    • The Company continues to enroll in KRYSTAL-10, a Phase 3 registrational clinical study in second-line colorectal cancer patients, evaluating the combination of adagrasib plus cetuximab versus chemotherapy. The Company expects to complete enrollment by year-end 2023.
    • Enrollment ongoing in KRYSTAL-12, a Phase 3 clinical study of adagrasib versus docetaxel in second line NSCLC. The Company plans to share data from this study in 2024.
    • The Company plans to share updated first-line NSCLC data of the combination of adagrasib with pembrolizumab and first-line development plans in the second half of 2023.

    Sitravatinib (Potent TAM receptor inhibitor)

    • The Company remains on track to provide topline final overall survival results from the global, registration-enabling Phase 3 SAPPHIRE study evaluating sitravatinib plus nivolumab (OPDIVO®)1 in second or third line non-squamous NSCLC in the second quarter of 2023. (View Release)

    MRTX1133 (Potent and selective KRASG12D inhibitor)

    • In March 2023, the Company began enrolling patients in the Phase 1/2 clinical study with plans for multiple expansion cohorts in pancreatic, colorectal, lung and other tumor types with KRASG12D mutations.

    MRTX1719 (MTA cooperative PRMT5 inhibitor)

    • The Company presented posters to highlight the mechanism by which MRTX1719 elicits potent and selective synthetic lethality in MTAP deleted tumors as well as the further enhancement of antitumor activity via rational targeted combination strategies at the 2023 American Association for Cancer Research (AACR) Annual Meeting. (View Release)
    • Enrollment is ongoing in the Phase 1/2 clinical study to evaluate MRTX1719, an MTA cooperative PRMT5 inhibitor, in patients with solid tumors harboring MTAP-gene deletions with plans to share initial clinical data from this study in the second half of 2023.

    MRTX0902 (Potent SOS1 inhibitor)

    • The Company presented preclinical data describing the ability of MRTX0902 to enhance anti-tumor activity and overcome acquired resistance in combination with either adagrasib, a potent and selective KRASG12C inhibitor, or an epidermal growth factor receptor inhibitor (e.g. osimertinib) at the 2023 AACR Annual Meeting. (View Release)
    • The Company continues to enroll in the Phase 1/2 clinical study evaluating MRTX0902, a selective KRAS signal modifying SOS1 inhibitor, in an escalating dose cohort as a monotherapy and expects to initiate dose escalation cohorts combining MRTX0902 and adagrasib in the second half of 2023.

    Recent Corporate Updates

    • In May 2023, the Company announced a strategic partnership with Sarah Cannon Research Institute aimed at increasing diversity in clinical study recruitment practices. (View Release)

    First Quarter Financial Results

    • Cash, cash equivalents and short-term investments of approximately $0.9 billion as of March 31, 2023.
    • Net KRAZATI ® product revenue for the first quarter 2023 was $6.3 million. There was no product revenue for the same period in 2022.
    • License and collaboration revenue for the first quarter 2023 was $0.9 million, compared to $0.7 million for the same period in 2022. Both periods represent clinical supply revenue earned under the agreement with Zai Lab.
    • Cost of product revenue for the first quarter 2023 was $0.8 million, of which $0.6 million related to product manufacturing and distribution costs, and royalties incurred on net sales of KRAZATI®, and $0.2 million represented non-cash amortization expense for our intangible asset. There was no cost of product revenue for the same period in 2022.
    • Research and development expenses for the first quarter 2023 were $126.7 million, compared to $131.0 million for the same period in 2022. The decrease in research and development expenses was primarily driven by a reduction in clinical development costs for sitravatinib as enrollment was completed in the SAPPHIRE Phase 3 clinical study in the second quarter of 2022, and lower clinical manufacturing costs to support ongoing clinical studies, partially offset by increases in costs for earlier stage clinical development programs such as MRTX1133, and an increase in salaries and other employee related expense to support portfolio advancement.
    • Selling, general and administrative expenses for the first quarter 2023 were $73.5 million, compared to $54.0 million for the same period in 2022. The increase in selling, general and administrative expenses was primarily due to an increase in headcount-related costs, including share-based compensation and salaries, and commercial-related costs to support the marketing and sales of KRAZATI®.
    • Net loss for the first quarter 2023 was $184.6 million, or $3.18 per share basic and diluted, compared to a net loss of $188.4 million, or $3.40 per share basic and diluted for the same period in 2022.
    • Net reduction in cash, cash equivalents and short-term investments for the first quarter was $181.5 million, which included 2022 annual bonus payments and a one-time cash payment of $15 million to Pfizer. The Company expects 2023 net cash burn to annualize within a range of $525 million to $580 million.

    Conference Call Information  

    There will be a conference call on May 9, 2023 at 4:30 p.m. ET / 1:30 p.m. PT during which company executives will review financial information for the first quarter and provide corporate updates.

    Investors and the general public are invited to listen to a live webcast of the call at the "Investors and Media" section on Mirati.com or by dialing the U.S. toll free +1 773-305-6853 or international +1 888-394-8218, confirmation code: 8109078.

    A replay of the call will be available approximately 2 hours after the event has ended at the same website.

    About Mirati Therapeutics, Inc.®

    Mirati Therapeutics, Inc. is a commercial stage biotechnology company whose mission is to discover, design and deliver breakthrough therapies to transform the lives of patients with cancer and their loved ones. The company is relentlessly focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. Unified for patients, Mirati's vision is to unlock the science behind the promise of a life beyond cancer.

    For more information about Mirati, visit us at Mirati.com or follow us on Twitter, LinkedIn, and Facebook.

    Forward Looking Statements

    This press release includes forward-looking statements regarding Mirati's business, financial guidance and the therapeutic and commercial potential of KRAZATI® (adagrasib), sitravatinib (TAM receptor inhibitor), MRTX1719 (MTA-cooperative PRMT5 inhibitor), MRTX0902 (SOS1 inhibitor), and MRTX1133 (selective KRASG12D inhibitor), Mirati's technologies and Mirati' other products in development. Any statement describing Mirati's goals, expectations, intentions or beliefs, financial or other projections, is a forward-looking statement and should be considered an at-risk statement. Such statements are subject to certain risks and uncertainties, including those inherent in the process of discovering, developing and commercializing medicines that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such medicines.

    Mirati's forward-looking statements also involve assumptions that, if they never materialize or prove correct, could cause its results to differ materially from those expressed or implied by such forward-looking statements. Although Mirati's forward-looking statements reflect the good faith judgment of its management, these statements are based only on facts and factors currently known by Mirati. As a result, you are cautioned not to rely on these forward-looking statements. These and other risks concerning Mirati's programs are described in additional detail in Mirati' annual report on Form 10-K, and most recent Form 10-Q, which are on file with the Securities and Exchange Commission and available at the SEC's Internet site (www.sec.gov). These forward-looking statements are made as of the date of this press release, and Mirati assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law.

    Mirati Contacts

    Investor Relations: [email protected]

    Media Relations: [email protected]

    1OPDIVO® (nivolumab) and the related logo are registered trademarks of Bristol-Myers Squibb Company

     

    Mirati Therapeutics, Inc.

    Consolidated Balance Sheets

    (unaudited)

    (in thousands)





    March 31,



    December 31,



    2023



    2022

    Assets







    Current assets







    Cash, cash equivalents and short-term investments

    $               902,294



    $           1,083,837

    Accounts receivable, net

    6,227



    865

    Inventory

    3,849



    3,020

    Other current assets

    26,980



    21,239

    Total current assets

    939,350



    1,108,961

    Property and equipment, net

    17,185



    17,540

    Intangible asset, net

    14,655



    14,914

    Long-term investment

    3,353



    3,465

    Right-of-use asset

    35,783



    36,122

    Other long-term assets

    23,435



    21,645

    Total assets

    $           1,033,761



    $           1,202,647









    Liabilities and Shareholders' Equity







    Current liabilities







    Accounts payable

    $                 22,320



    $                 38,861

    Accrued liabilities

    102,280



    120,587

    Total current liabilities

    124,600



    159,448

    Lease liability

    43,227



    43,661

    Other liabilities

    3,304



    3,022

    Total liabilities

    171,131



    206,131









    Shareholders' equity

    862,630



    996,516









    Total liabilities and shareholders' equity

    $           1,033,761



    $           1,202,647

     

    Mirati Therapeutics, Inc.

    Consolidated Statements of Operations and Comprehensive Loss

    (unaudited)

    (in thousands, except per share data)





    Three Months Ended

    March 31,



    2023



    2022



    (unaudited)

    Revenue







    Product revenue, net

    $                    6,291



    $                            —

    License and collaboration revenues

    876



    709

    Total revenue

    7,167



    709

    Expenses







    Cost of product revenue

    558



    —

    Cost of product revenue - intangible asset amortization

    259



    —

    Research and development

    126,683



    130,976

    Selling, general and administrative

    73,490



    53,951

    Total operating expenses

    200,990



    184,927

    Loss from operations

    (193,823)



    (184,218)

    Other income (expense), net

    9,237



    (4,168)

    Net loss

    $             (184,586)



    $             (188,386)

    Unrealized gain (loss) on available-for-sale investments

    2,043



    (4,802)

    Foreign currency translation adjustment

    (31)



    —

    Comprehensive loss

    $             (182,574)



    $             (193,188)

    Net loss per share, basic and diluted

    $                     (3.18)



    $                     (3.40)

    Weighted average common shares outstanding, basic and diluted

    58,032



    55,469

     

    Logo (PRNewsfoto/Mirati Therapeutics, Inc.)

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/mirati-therapeutics-reports-first-quarter-2023-financial-results-and-recent-corporate-updates-301820023.html

    SOURCE Mirati Therapeutics, Inc.

    Get the next $MRTX alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $MRTX

    DatePrice TargetRatingAnalyst
    8/10/2023$51.00 → $48.00Neutral → Buy
    Citigroup
    8/9/2023$45.00Neutral → Buy
    B. Riley Securities
    8/9/2023$45.00Overweight
    Piper Sandler
    7/27/2023Sector Underperform
    Scotiabank
    5/25/2023Perform → Outperform
    Oppenheimer
    12/14/2022Hold
    Needham
    12/9/2022$121.00 → $53.00Buy → Neutral
    Citigroup
    12/8/2022$110.00 → $59.00Outperform → Market Perform
    BMO Capital Markets
    More analyst ratings

    $MRTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G filed by Mirati Therapeutics Inc.

      SC 13G - Mirati Therapeutics, Inc. (0001576263) (Subject)

      2/14/24 4:21:54 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Mirati Therapeutics Inc. (Amendment)

      SC 13G/A - Mirati Therapeutics, Inc. (0001576263) (Subject)

      2/14/24 2:51:56 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G/A filed by Mirati Therapeutics Inc. (Amendment)

      SC 13G/A - Mirati Therapeutics, Inc. (0001576263) (Subject)

      2/14/24 9:13:21 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRTX
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • European Commission Approves KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

      SAN DIEGO and ZUG, Switzerland, Jan. 10, 2024 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, today announced that the European Commission (EC) granted conditional marketing authorization for KRAZATI® (adagrasib) as a targeted treatment option for adult patients with KRASG12C -mutated advanced non-small cell lung cancer (NSCLC) and disease progression after at least one prior systemic therapy. KRAZATI has demonstrated a positive benefit-risk profile based on the Phase 2 registration-enabling cohort of the KRYSTAL-1 study, evaluating KRAZATI 600 mg administered orally twice daily in 116 patients with KRASG12C-mutated advanced NSCLC who previ

      1/10/24 8:00:00 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC

      SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ:KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and Mirati Therapeutics, Inc. (NASDAQ:MRTX), a commercial-stage targeted oncology company, today announced a clinical collaboration and supply agreement to evaluate the combination of KO-2806, a next-generation farnesyl transferase inhibitor (FTI), and adagrasib, a highly selective KRASG12C inhibitor, in patients with KRASG12C-mutated non-small cell lung cancer (NSCLC). "Recent findings suggest that combining KO-2806 with adagrasib can drive tumor regressions and enhance both durati

      11/2/23 7:30:00 AM ET
      $KURA
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Bristol Myers Squibb Strengthens and Diversifies Oncology Portfolio With Acquisition of Mirati Therapeutics

      Bristol Myers Squibb to Acquire Mirati for $58.00 Per Share, Representing $4.8 Billion Equity Value and Up to $5.8 Billion Including the Contingent Value Right Acquisition Brings KRAZATI® (adagrasib), a Best-in-Class KRASG12C Inhibitor Approved by the U.S. FDA for the Treatment of Patients with Advanced Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation and Who Have Received at Least One Prior Systemic Treatment KRAZATI is in Clinical Development in Combination with a PD-1 Inhibitor as a First-Line Therapy for Patients with Non-Small Cell Lung Cancer Harboring a KRASG12C Mutation as well as in Other Indications Mirati's Promising Pipeline Includes a Potent Selective PRMT5/MTA Inh

      10/8/23 5:16:00 PM ET
      $BMY
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Mirati Therapeutics upgraded by Citigroup with a new price target

      Citigroup upgraded Mirati Therapeutics from Neutral to Buy and set a new price target of $48.00 from $51.00 previously

      8/10/23 7:25:39 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirati Therapeutics upgraded by B. Riley Securities with a new price target

      B. Riley Securities upgraded Mirati Therapeutics from Neutral to Buy and set a new price target of $45.00

      8/9/23 8:29:32 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Piper Sandler resumed coverage on Mirati Therapeutics with a new price target

      Piper Sandler resumed coverage of Mirati Therapeutics with a rating of Overweight and set a new price target of $45.00

      8/9/23 7:36:39 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRTX
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Boxer Capital, Llc returned 6,859,544 shares to the company (SEC Form 4)

      4 - Mirati Therapeutics, Inc. (0001576263) (Issuer)

      1/25/24 4:32:24 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cherrington Julie M returned 11,252 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Mirati Therapeutics, Inc. (0001576263) (Issuer)

      1/23/24 8:38:07 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Sharp Shalini returned 16,222 shares to the company, closing all direct ownership in the company (SEC Form 4)

      4 - Mirati Therapeutics, Inc. (0001576263) (Issuer)

      1/23/24 8:38:09 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRTX
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    See more
    • FDA Approval for KRAZATI issued to MIRATI THERAPEUTICS, INC

      Submission status for MIRATI THERAPEUTICS, INC's drug KRAZATI (ORIG-1) with active ingredient ADAGRASIB has changed to 'Approval' on 12/12/2022. Application Category: NDA, Application Number: 216340, Application Classification: Type 1 - New Molecular Entity

      12/14/22 7:40:10 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for KRAZATI (ADAGRASIB) issued to MIRATI THERAPEUTICS, INC

      Submission status for MIRATI THERAPEUTICS, INC's drug KRAZATI (ADAGRASIB) (ORIG-1) with active ingredient ADAGRASIB has changed to 'Approval' on 12/12/2022. Application Category: NDA, Application Number: 216340, Application Classification: Type 1 - New Molecular Entity

      12/12/22 6:09:02 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • FDA Approval for KRAZATI (ADAGRASIB) issued to MIRATI THERAPEUTICS, INC

      Submission status for MIRATI THERAPEUTICS, INC's drug KRAZATI (ADAGRASIB) (ORIG-1) with active ingredient ADAGRASIB has changed to 'Approval' on 12/12/2022. Application Category: NDA, Application Number: 216340, Application Classification: Efficacy

      12/12/22 4:56:01 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRTX
    Financials

    Live finance-specific insights

    See more
    • Mirati Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Updates

      Shares plans to initiate Phase 3 combination study evaluating adagrasib with pembrolizumab in first line non-small cell lung cancer in patients with TPS ≥ 50% Announces compelling initial clinical data for MRTX1719 in MTAP-deleted cancers demonstrating favorable safety profile and early signs of strong clinical activity David Meek to depart Company, Charles M. Baum, M.D., Ph.D., President and Founder, to assume role of interim CEO during search for permanent CEO Company will announce financial results for the second quarter 2023 along with recent corporate updates during a conference call at 5:30 p.m. ET / 2:30 p.m. PT SAN DIEGO, Aug. 8, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASD

      8/8/23 4:01:00 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirati Therapeutics® to Report Second Quarter 2023 Financial Results and Recent Corporate Updates on August 8, 2023

      SAN DIEGO, July 25, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a commercial stage biotechnology company, will announce financial results for the second quarter 2023 along with recent corporate updates on August 8, 2023. During a conference call at 4:30 p.m. ET / 1:30 p.m. PT on August 8, company executives will provide company updates and review financial results. Investors and the general public are invited to listen to a live webcast of the call at the "Investors and Media" section on Mirati.com or by dialing the U.S. toll free +1 773-305-6853 or international +1 888-394-8218, confirmation code: 6674271. A replay of the call will be available approximately 2 hours after

      7/25/23 4:30:00 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirati Therapeutics Reports First Quarter 2023 Financial Results and Recent Corporate Updates

      SAN DIEGO, May 9, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, today announced financial results for the first quarter 2023 along with recent pipeline and corporate updates. "Today we are pleased to share the significant progress made during the first quarter of 2023, highlighted by our first full quarter of sales for KRAZATI®, which we believe is the best-in-class KRASG12C inhibitor. This is just the beginning of our journey with KRAZATI®, as we continue to advance our broad development plan in lung cancer and across other indications and lines of therapy," said David Meek, chief executive officer, Mirati Therapeutics, Inc. "In add

      5/9/23 4:01:00 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRTX
    SEC Filings

    See more
    • SEC Form 15-12G filed by Mirati Therapeutics Inc.

      15-12G - Mirati Therapeutics, Inc. (0001576263) (Filer)

      2/2/24 4:05:54 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Mirati Therapeutics Inc.

      EFFECT - Mirati Therapeutics, Inc. (0001576263) (Filer)

      1/25/24 12:15:14 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form EFFECT filed by Mirati Therapeutics Inc.

      EFFECT - Mirati Therapeutics, Inc. (0001576263) (Filer)

      1/25/24 12:15:09 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $MRTX
    Leadership Updates

    Live Leadership Updates

    See more
    • Mirati Therapeutics Appoints Industry Veteran Carol Gallagher, Pharm.D. as New Independent Director

      SAN DIEGO, June 23, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc.® (NASDAQ:MRTX), a commercial stage biotechnology company, today announced its Board of Directors has appointed a new independent director, Dr. Carol Gallagher. "I am pleased to welcome Dr. Gallagher to our Board during this pivotal time for the company," said David Meek, chief executive officer, Mirati Therapeutics, Inc. "Carol brings a tremendous amount of biopharmaceutical and leadership experience, and her insights will be significant as we continue to advance our mission to positively impact the lives of people living with cancer." Dr. Gallagher has over 30 years of strategic, commercial, business development and drug dev

      6/23/23 4:00:00 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Mirati Therapeutics Appoints Alan Sandler, M.D., as Executive Vice President and Chief Medical Officer, Shares Update to Executive Leadership Team

      Charles M. Baum, M.D., Ph.D., President, Founder and head of R&D to retire 2Q 2023 following over a decade of Mirati leadership, driving corporate transformation SAN DIEGO, Nov. 8, 2022 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, today announced the appointment of Alan Sandler, M.D., to the position of executive vice president and chief medical officer. In his role, Dr. Sandler will provide leadership and direction over clinical development and operations, regulatory affairs, drug safety and asset development strategy and report to David Meek, chief executive officer. As part of the transition, Dr. James Christensen, executive vice pr

      11/8/22 4:05:00 PM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • ImmunOs Therapeutics Announces Appointment of Joseph Leveque, MD, to its Board of Directors

      - Seasoned immuno-oncology executive brings significant medical and biopharma expertise Schlieren (Zurich Area), Switzerland, and Gaithersburg, MD, USA – October 4, 2022 – ImmunOs Therapeutics AG, a biopharmaceutical company leveraging its HLA-based technology platform to develop first-in-class therapeutics for the treatment of cancer and autoimmune diseases, today announced that Joseph Leveque, MD, has been appointed to the Company´s Board of Directors. Dr. Leveque has over a decade of experience in the development of immuno-oncology therapeutics. He is currently President, Chief Medical Officer, and a Board Member of Medikine. Prior to Medikine, he was Executive Vice President a

      10/4/22 4:00:00 AM ET
      $MRTX
      Biotechnology: Pharmaceutical Preparations
      Health Care